NCT00336219Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)GERD
NCT00163306Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)Gastroesophageal Reflux
Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)
symptom assessment as measured by ReQuest™ questionnaire and investigator.
28 days
Response to treatment with pantoprazole at week 8, as measured by the questionnaire ReQuest™
8 weeks
complete reflux disease remission rate after 8 weeks of treatment defined as symptom relief assessed by reflux questionnaire (ReQuest Trademark) and endoscopically confirmed healing.
Safety (adverse events, laboratory values).
5 years
Secondary Endpoints
symptom assessment on days 7, 14, and 28 as measured by ReQuest™ questionnaire and investigator
Main Inclusion Criteria:
* Written informed consent
* Outpatients
* History of GERD-related symptoms for at least 6 months prior to study inclusion
* Endoscopically confirmed erosive GERD or non-erosive GERD
Main Exclusion Criteria:
* Acute peptic ulcer and/or ulcer complications
* PPIs during la...